Compare Equinor ASA (EQNR) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs Heron Therapeutics Inc — how do they compare? Equinor ASA trades at $35.63 (market cap $82.75B), while Heron Therapeutics Inc trades at $0.45 (market cap $84.50M). The key difference: Equinor ASA is far larger — about 979.3× Heron Therapeutics Inc's market cap, and Equinor ASA pays a 4.24% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| EQNR | HRTX | |
|---|---|---|
Market Cap | $82.75B | $84.50M |
Sector | Energy | Health |
52-Week High | $42.40 | $2.02 |
52-Week Low | $22.41 | $0.39 |
Enterprise Value | $94.51B | $182.40M |
Dividend Yield | 4.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EQNR trades at $36.19, up 0.36% on the day, with a bullish technical signal from moving averages. Recent earnings show mixed results, with a Q1 2026 beat but a Q3 2025 miss. The company maintains a strong balance sheet with $21.24B in cash and a low EV/EBITDA of 2.39. Recent news highlights strategic investments in subsea projects and a share buy-back program, reinforcing growth commitments.
The outlook is cautiously optimistic, supported by low valuation metrics and strategic asset expansions. Key risks include volatile energy prices and declining net income margins. Analyst sentiment is mixed, with a 30.43% buy rating, suggesting potential upside but requiring monitoring of execution on production targets.
HRTX trades at $0.44, up 2.63% today, with a bullish technical signal but bearish moving averages. The company reported Q1 2026 revenue of $151M with a net loss of $31M, maintaining a negative profit margin of -20.53%. Recent patent litigation developments and mixed earnings performance create uncertainty, though analyst consensus remains overwhelmingly positive with 94.7% buy ratings.
The outlook remains challenging with persistent losses and negative cash flow from operations, though improving net cash flow trends offer some optimism. Key risks include ongoing patent litigation and execution challenges in achieving profitability. The strong analyst support suggests potential upside if the company can deliver on its guidance and improve operational efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
